Active Ingredient(s):Tositumomab FDA Approved: * June 27, 2003 Pharm Company: *CORIXA Category:Cancer
Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma. It is classified as a IgG2a lambda antibody.
The drug combination was developed by Corixa which was purchased by GlaxoSmithKline in...
* May have multiple approval dates, manufacturers, or labelers.